Description
Springer Methods Of Cancer Diagnosis Therapy And Prognosis General Overviews Head And Neck Cancer And Thyroid Cancer 2010 Edition by M. A. Hayat
There are more than 100 types of cancers In Part II head and neck cancer is d- affecting all parts of the human body. cussed. The global number of annual new More than 11 million people are diagnosed cases of this malignancy is ~500000. These with cancer every year and it is estimated malignancies include oral squamous cell that there will be 16 million new cases by carcinoma salivary gland tumors tons- the year 2020. In 2005 7. 6 million peo- lar cancer tongue cancer nasopharyngeal ple died of cancer that is 13% of the 58 carcinoma and retinoblastoma which are million deaths worldwide. It is estimated detailed. In Part III diagnosis therapy and that 9 million people will die from can- prognosis of thyroid carcinoma are d- cer worldwide in 2015 and 11. 4 million cussed. The global number of new cases of will die in 2030. More than 70% of all thyroid cancer is ~141000 and the number cancer deaths occur in low and middle of worldwide thyroid mortalities is ~35375. income countries. These statistics underlie The number of new cases of this cancer in the fact that cancer is the deadliest of all the United States is ~33550. Molecular human diseases. The enormity of the glo- genetics of thyroid cancer gene expr- bal healthcare costs as a result of cancer sion markers for diagnosis papillary t- cannot be overemphasized. Table of contents : PART I. GENERAL METHODS AND OVERVIEWSDiagnosis1. ROLE OF RNA INTERFERENCE IN UNDERSTANDING THE MOLECULAR BASIS OF CANCER; Jeffrey P. MacKeigan and Alex GaitherMECHANISM OF RNA INTERFERENCERNA INTERFERENCE AS A CELL BASED SCREENING TOOLRNA INTERFERENCE TO UNDERSTAND COMPOUND MECHANISM OF ACTIONCOMPOUND SENSITIZATION COMBINATION STRATEGIES AND SYNTHETIC LETHAL RNA INTERFERENCE SCREENSPROBLEMS ASSOCIATED WITH RNA INTERFERENCE BASED APPROACHESREFERENCES2. CANCER BIOMARKERS (AN OVERVIEW); William C.S. ChoINTRODUCTIONEMERGING TECHNOLOGIES FOR CANCER BIOMARKER DISCOVERYDNA MicroarraySerial Analysis of Gene ExpressionMicroRNA MicroarrayTwo Dimensional Polyacrylamide Gel ElectrophoresisFree Flow ElectrophoresisCapillary ElectrophoresisMatrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass SpectrometrySurface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass SpectrometryLiquid Chromatography Coupled with Tandem Mass SpectrometryLinear Ion Trap Quadrupole-OrbitrapImaging Mass SpectrometryIsotope-Coded Affinity TagsMultiple Reaction MonitoringAbsolute Quantification of ProteinsProtein MicroarrayTissue ArrayBioinformaticsCURRENTLY USED CANCER BIOMARKERSBIOMARKERS FOR THE DIAGNOSIS OF CANCERSGenomic-based Biomarkers in CancerTranscriptomic-based Biomarkers in CancerProteomic-based Biomarkers in CancerBIOMARKERS FOR THE TREATMENT AND PROGRESSION OF CANCERSGenomic-based Biomarkers in CancerTranscriptomic-based Biomarkers in CancerProteomic-based Biomarkers in CancerBIOMARKERS FOR THE PROGNOSIS OF CANCERSGenomic-based Biomarkers in CancerTranscriptomic-based Biomarkers in CancerProteomic-based Biomarkers in CancerCHALLENGES AND PERSPECTIVESREFERENCES3. TUMOR ANGIOGENESIS IN CANCERS: EXPRESSION OF CD105 MARKER; Osamu Tokunaga Rahmawati Minhajat and Daisuke MoriINTRODUCTION MORPHOLOGICAL FEATURES OF TUMOR ANGIOGENESISDETECTION OF THE ENDOTHELIUM IMMUNOHISTOLOGYAntigenecity RetrievalImmunohistologySIMULTANEOUS MASS AND COMPARATIVE STUDY: TISSUE ARRAYSPECIFIC MARKERS FOR VASCULAR ENDOTHELIUM IN TUMORSAngiogenesisCD105/ENDOGLIN ENDOTHELIAL MARKER SPECIFIC FOR NEWLYFORMED BLOOD VESSELSCD105 AND VASCULOGENESISORGAN SPECIFICITY OF CD105 POSITIVE TUMOR ANGIOGENESISAPPLICATION OF CD105 FOR ANTI-ANGIOGENIC CANCER THERAPYREFERENCES4. SPINDLE CELL ONCOCYTOMA OF THE ADENOHYPOPHYSIS: INTEGRATED CLINICOPATHOLOGIC DIAGNOSIS BY IMAGING HISTOLOGY AND IMMUNOHISTOCHEMISTRY; Istvan Vajtai and Rahel SahliINTRODUCTIONCLINICAL PRESENTATION IMAGING ASPECTSHISTOLOGY AND IMMUNOPHENOTYPEDIFFERENTIAL DIAGNOSISTHERAPEUTIC AND PROGNOSTIC IMPLICATIONSDISCUSSION AND PERSPECTIVESREFERENCES5. DISSEMINATED CARCINOMA OF UNKNOWN PRIMARY SITE: DETECTION WITH F-FLUORODEOXYGLUCOSE- POSITRON EMISSION TOMOGRAPHY; Pascal Seve and John R. MackeyINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES6. UNKNOWN LYMPHADENOPATHY: DIAGNOSIS USING AN ENDOSCOPIC ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION; Ichiro YasudaINTRODUCTIONAPPLICATIONEQUIPMENTPROCEDUREDIAGNOSTIC YIELDREFERENCESTherapy7. PRETARGETED RADIOIMMUNOTHERAPY IN CANCER: AN OVERVIEW; Stefano Papi Chiara Maria Grana Mirco Bartolomei Laura Ravasi Marta Cremonesi Mahila Ferrari Luigi Martano Lucia Garaboldi Marco Chinol and Giovanni PaganelliINTRODUCTIONTHERAPEUTIC RADIOISOTOPESLIMITATIONS OF CLASSICAL